Placeholder Banner

BIO comments to USTR on the Agency’s 2023 Special 301 Review, January 30, 2023

January 31, 2023
Download Full Comments Below
BIO_2023%20Special%20301_Review_Comment%20.pdf
Discover More
FTC HSR Comments
Comments on Revised HSR Premerger Notification and Report Form 16 CFR Parts 801-803—Hart-Scott-Rodino Coverage, Exemption, and Transmittal Rules,…
BIO Board Vice Chair and CEO of Amicus Therapeutics testified that the drug price controls in the Inflation Reduction Act harm drug research and development.